3,5-diiodothyronine, (l)-isomer has been researched along with 3,3',5-triiodothyroacetic acid in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Actis, M; Evison, B; Fujii, N; Inoue, A; Perry, S; Punchihewa, C | 1 |
Arifi, S; Bischoff, I; Chaikuad, A; Fürst, R; Gellrich, L; Goebel, T; Heering, J; Heitel, P; Kahnt, A; Kilu, W; Knapp, S; Merk, D; Paulke, A; Pogoda, W; Pollinger, J; Proschak, E; Schubert-Zsilavecz, M; Steinhilber, D; Wurglics, M | 1 |
2 other study(ies) available for 3,5-diiodothyronine, (l)-isomer and 3,3',5-triiodothyroacetic acid
Article | Year |
---|---|
Small molecule inhibitors of PCNA/PIP-box interaction suppress translesion DNA synthesis.
Topics: Amino Acid Sequence; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA; DNA Damage; DNA Replication; HeLa Cells; Humans; Neoplasms; Proliferating Cell Nuclear Antigen; Protein Interaction Maps; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
Topics: Amino Acid Sequence; Animals; Drug Evaluation, Preclinical; Male; Mice; Models, Molecular; PPAR gamma; Protein Conformation; Thyroxine | 2020 |